Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mg
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome
Conditions
Metabolic Syndrome
Trial Timeline
Oct 1, 2016 → Feb 1, 2018
NCT ID
NCT02968160About Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mg
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mg is a approved stage product being developed by Yuhan for Metabolic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02968160. Target conditions include Metabolic Syndrome.
What happened to similar drugs?
18 of 20 similar drugs in Metabolic Syndrome were approved
Approved (18) Terminated (3) Active (2)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02968160 | Approved | Terminated |
Competing Products
20 competing products in Metabolic Syndrome